State-of-the-art pharmacological approaches to reduce chorea in Huntington’s disease
Jessie S. Gibson, Daniel O. Claassen
Abstract
: Treatment considerations for chorea should account for patient comorbidities. The authors recommend prospective, observational clinical effectiveness studies which can evaluate the long-term comparative effectiveness and safety of VMAT-2 inhibitors and antipsychotics in HD. Data regarding safety of dual therapy is another critical need. This is especially timely given the changing landscape of HD therapies which may increase cost burden and possibly extend both asymptomatic and symptomatic years for HD patients.
Topics & Concepts
ChoreaMedicineTetrabenazinePsychiatryTolerabilityAntipsychoticDeep brain stimulationObservational studyClinical trialDiseaseIntensive care medicinePediatricsInternal medicineSchizophrenia (object-oriented programming)Adverse effectParkinson's diseaseDopamineGenetic Neurodegenerative DiseasesNeurological disorders and treatmentsParkinson's Disease Mechanisms and Treatments